Search

469 Result(s)
Sort by

Making sustainable medicines through eco-design

Making sustainable medicines through eco-design

Our goal is to minimize the environmental footprint of our medicines through integration of eco-design and green chemistry across the entire lifecycle
FDA approval NexGard PLUS for dogs

FDA approval NexGard PLUS for dogs

Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS - A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites
Xochimilco

Xochimilco

The site in Xochimilco, Mexico, focuses on pharmaceutical production for both Human Pharma and Animal Health.
1885-1948: Innovative beginnings

1885-1948: Innovative beginnings

The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products
CHMP_opinion_Nintedanib_SSc-ILD

CHMP_opinion_Nintedanib_SSc-ILD

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Koropi

Koropi

For more than 45 years, the company has been producing pharmaceuticals in its production facility in Koropi, Greece.
ivomec

ivomec

Depending on formulation, the product is for the treatment of nematodes, lice, mites, ticks, flies, lungworms and liver flukes.
Eprinex®

Eprinex®

Depending on formulation, the product is for the treatment of nematodes, lice, mites, ticks, flies and lungworms in cattle and sheep.
Vienna

Vienna

Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Ingelvac PRRS

Ingelvac PRRS

Depending on the product, for the active immunisation of pigs at various ages against porcine reproductive and respiratory syndrome virus (PRRSV).
Where to meet us

Where to meet us

Find out where to meet the BD&L team virtually or in person at the next conference or event. Submit your opportunity to our BD&L team here.